Target intelligence / Profile preview

Ras association domain family member 1 (RASSF1)

Target
RASSF1
Molecular classification
Tumor suppressor, Scaffold protein, Ras effector family member, Other
01

Overview

Ras association domain family member 1 (RASSF1) is a tumor suppressor protein that acts as a molecular scaffold and is involved in regulation of cell cycle arrest, apoptosis, microtubule stabilization, and inhibition of tumorigenesis[1][2][3][4]. The RASSF1 gene produces multiple isoforms, with RASSF1A and RASSF1C being the most abundant in normal tissues. RASSF1A binds to and stabilizes microtubules, suppresses cyclin D1 and cyclin A2 accumulation, and promotes cell cycle arrest and apoptosis, in part through modulation of the Hippo pathway and through interactions with Ras GTPases[1][2][4]. Loss of RASSF1A function, commonly via promoter hypermethylation, is strongly associated with the pathogenesis of many cancers, highlighting its role as a frequent tumor suppressor inactivation event in oncogenesis[1][3][6]. RASSF1A interacts with multiple signaling and structural proteins—including Ras, microtubule-associated proteins, death receptors, and Hippo pathway kinases—coordinating responses to DNA damage, mitogenic stimuli, and pro-apoptotic signals[2][4]. It is widely studied as a biomarker for cancer diagnosis and prognosis, especially through detection of its promoter methylation status[1][6]. There are currently no approved drugs directly targeting RASSF1, but epigenetic therapy to restore its function is an area of research.

Other names
Ras association domain-containing protein 1RDA32NORE2AREH3P21123F2RASSF1ARas association (RalGDS/AF-6) domain family member 1
02

Biological functions

Regulation of cell cycleApoptosisMicrotubule stabilizationModulation of Ras, Rho, and Hippo signaling pathwaysCell proliferation inhibitionDNA repair regulation
03

Disease associations

Cancer (notably lung, breast, gastric, liver, colorectal, and cervical cancer)Other (epigenetic inactivation implicated in tumorigenesis)
04

Safety considerations

Restoration or targeting of RASSF1 function as a therapeutic approach is largely experimental; risks and safety challenges are not fully characterized.Epigenetic therapies aiming to reactivate RASSF1A may have off-target effects.
05

Biomarkers

RASSF1A promoter hypermethylation (associated with cancer diagnosis and prognosis)

Beyond the preview

Go deeper on Ras association domain family member 1 (RASSF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras association domain family member 1 (RASSF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call